GlassScriptPhysician profile
Christian Coletta
NPI 1821592718
$3,408.36
in general payments reported to CMS, 2019-2025
22 companies · $1,075 in 2025
The $1,075 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.32 · 2020: $11.72 · 2022: $1,000 · 2023: $489 · 2024: $810 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286 · Education: $79.99 · Consulting Fee: $8.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.63 |
| Education | $79.99 |
| Consulting Fee | $8.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Genzyme Corporation | $429.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $373.76 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $316.67 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $288.34 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $154.79 | 2024-2025 | Hyqvia, Cuvitru, Takhzyro |
| Teva Pharmaceuticals USA, INC. | $122.11 | 2023 | Uzedy |
| Optinose US, INC. | $108.13 | 2024-2025 | |
| Amgen INC. | $89.69 | 2024-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $80.35 | 2024-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Grifols USA, LLC | $71.01 | 2024-2025 | Xembify |
| Hikma Pharmaceuticals USA | $57.10 | 2023-2025 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $54.04 | 2025 | Dawnzera |
| Genentech USA, INC. | $35.60 | 2024-2025 | Xolair |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $34.04 | 2019-2020 | |
| Csl Behring | $31.05 | 2023-2025 | Hizentra, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $20.58 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $20.31 | 2025 | |
| Blueprint Medicines Corporation | $17.84 | 2024 | Ayvakit |
| Kaleo, INC. | $14.80 | 2024 | Auvi-Q |
| Adma Biomanufacturing LLC | $8.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Coletta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.